The investment seeks long-term growth of capital. The fund invests at least 80% of total assets in equity securities of U.S. and foreign healthcare companies and biotechnology companies, regardless of their stock market value (or market capitalization), including common stocks, preferred stocks, securities convertible into common stocks and warrants. The fund is nondiversified.
0.10 (0.64%) 